Value proposition

Delivering the Power of T Cells to Cancer Patients

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Read more about Immatics on our homepage: https://immatics.com/

Find us also on:
Twitter: https://twitter.com/immatics
Instagram: https://www.instagram.com/immatics/
YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA

Legal notice: https://immatics.com/imprint/

Discovery of HLA-restricted tumor-associated peptides as cancer targets, Biomarkers, Immunomonitoring, Peptidomics & mass spectrometry, Standardized PBMC collection, Bioinformatics, Immunology, TCR Discovery, Bispecific Development, TCR-based Immunotherapies, Adoptive Cell Therapy, TCR Bispecifics, and Cancer